MX2019002617A - Induccion de memoria inmune por compuestos basados en platino. - Google Patents

Induccion de memoria inmune por compuestos basados en platino.

Info

Publication number
MX2019002617A
MX2019002617A MX2019002617A MX2019002617A MX2019002617A MX 2019002617 A MX2019002617 A MX 2019002617A MX 2019002617 A MX2019002617 A MX 2019002617A MX 2019002617 A MX2019002617 A MX 2019002617A MX 2019002617 A MX2019002617 A MX 2019002617A
Authority
MX
Mexico
Prior art keywords
based compounds
platinum based
immune memory
present
memory induction
Prior art date
Application number
MX2019002617A
Other languages
English (en)
Inventor
SENGUPTA Aniruddha
MYLAVARAPU Sanghamitra
Roy Monideepa
Sengupta Shiladitya
Original Assignee
Akamara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akamara Therapeutics Inc filed Critical Akamara Therapeutics Inc
Publication of MX2019002617A publication Critical patent/MX2019002617A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un método para tratar el cáncer o su recidiva en mamíferos mediante el uso de compuestos basados en platino. Más particularmente, la presente invención proporciona una mejora para la inmunidad en un mamífero, usando un compuesto de Fórmula I y/o Fórmula II, preferiblemente el Compuesto 1 o su derivado, sal, forma tautomérica, isómero, polimorfo, solvato o productos intermedios de los mismos. El método de inducir una respuesta inmune en un mamífero es mediado a través de la memoria inmune. La presente invención también proporciona dichos compuestos basados en platino y su uso en el tratamiento del cáncer, la metástasis o la recidiva del cáncer.
MX2019002617A 2016-09-07 2017-09-07 Induccion de memoria inmune por compuestos basados en platino. MX2019002617A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611030627 2016-09-07
PCT/IB2017/055394 WO2018047090A1 (en) 2016-09-07 2017-09-07 Immune memory induction by platinum based compounds

Publications (1)

Publication Number Publication Date
MX2019002617A true MX2019002617A (es) 2019-09-19

Family

ID=60245130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002617A MX2019002617A (es) 2016-09-07 2017-09-07 Induccion de memoria inmune por compuestos basados en platino.

Country Status (10)

Country Link
US (1) US20190209513A1 (es)
EP (1) EP3509603B1 (es)
JP (1) JP2019529539A (es)
KR (1) KR20190045295A (es)
CN (1) CN109963568A (es)
AU (1) AU2017323593A1 (es)
CA (1) CA3036128A1 (es)
ES (1) ES2972710T3 (es)
MX (1) MX2019002617A (es)
WO (1) WO2018047090A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020168283A1 (en) * 2019-02-14 2020-08-20 Akamara Therapeutics, Inc. Compounds and methods for managing cancer through immune system
KR102500643B1 (ko) 2019-04-18 2023-02-16 한미약품 주식회사 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501568A (ja) * 1985-10-18 1988-06-16 ボ−ド・オブ・リ−ジェンツ、ザ・ユニバ−シティ−・オブ・テキサス・システム リポソ−ムに有効に組み込まれた疎水性シス−プラチナ複合体
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
ITMI20020992A1 (it) * 2002-05-10 2003-11-10 Ice Srl Complessi di platino contenenti acidi biliari chimicamente modificatiad attivita' antitumorale
JP5844642B2 (ja) * 2009-02-04 2016-01-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． ナノスケール白金化合物およびその使用方法
WO2014201376A2 (en) * 2013-06-14 2014-12-18 Invictus Oncology Pvt. Ltd. Lipid-based platinum compounds and nanoparticles
KR20160132496A (ko) * 2014-04-03 2016-11-18 인빅터스 온콜로지 피비티. 엘티디. 초분자 조합 치료제
CN104610415B (zh) * 2014-11-13 2016-05-25 昆明贵金属研究所 肝靶向铂类抗癌药物及其合成方法

Also Published As

Publication number Publication date
US20190209513A1 (en) 2019-07-11
EP3509603A1 (en) 2019-07-17
CN109963568A (zh) 2019-07-02
EP3509603C0 (en) 2024-01-03
WO2018047090A1 (en) 2018-03-15
JP2019529539A (ja) 2019-10-17
AU2017323593A1 (en) 2019-04-11
ES2972710T3 (es) 2024-06-14
KR20190045295A (ko) 2019-05-02
CA3036128A1 (en) 2018-03-15
EP3509603B1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
EA201890522A1 (ru) Способ получения противогрибковых соединений
CY1121395T1 (el) Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6
EA202092609A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201792067A1 (ru) Противогрибковые соединения и способы получения
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
EA201790983A1 (ru) Синтез копанлисиба и его дигидрохлорида
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
EA201892515A1 (ru) Стероидные 6,7-бета-эпоксиды в качестве интермедиатов
PH12016501941A1 (en) Use of heterocyclic compounds for controlling nematodes
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
IL279725A (en) Pyridine and pyrazine compounds as cannabinoid receptor 2 inhibitors
BE1022355A1 (fr) Nouvelles méthodes d'induction d'une réponse immunitaire
MX2019002617A (es) Induccion de memoria inmune por compuestos basados en platino.
AR099071A1 (es) Antagonistas selectivos de nr2b
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
SG10201810263QA (en) Nampt inhibitors and methods
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
MX2021000547A (es) Extracto liquido de schoenocaulon.
AR103380A1 (es) Método de producción de derivado de tiazol
UA117702C2 (uk) Поліморфи (9-дихлорметилен-1,2,3,4-тетрагідро-1,4-метанонафталін-5-іл)-аміду 3-дифторметил-1-метил-1h-піразол-4-карбонової кислоти